1 Ashley Road
3rd Floor
Altrincham WA14 2DT
United Kingdom
https://www.centessa.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 76
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Saurabh Saha M.D., Ph.D. | CEO & Director | 965,89k | N/D | 1976 |
Dr. David M. Chao Ph.D. | Chief Administrative Officer | 658,54k | N/D | 1968 |
Dr. Antoine Yver M.D., M.Sc. | Executive VP & Chairman of Development | 716,8k | N/D | 1958 |
Dr. Gregory M. Weinhoff M.B.A., M.D. | Principal Accounting Officer & CFO | 607,27k | N/D | 1971 |
Ms. Tia L. Bush | Chief Technology & Quality Officer | N/D | N/D | 1971 |
Ms. Kristen K. Sheppard Esq., J.D. | Senior Vice President of Investor Relations & Corporate Communications | N/D | N/D | N/D |
Mr. Iqbal J. Hussain L.L.B. | General Counsel, Chief Compliance Officer & Corporate Secretary | N/D | N/D | 1981 |
Ms. Karen M. Anderson | Chief People Officer | N/D | N/D | 1968 |
Dr. Harris L. Rotman Ph.D. | Senior Vice President of Regulatory Affairs | N/D | N/D | N/D |
Dr. Patrick Yue M.D. | Senior VP of Clinical Development & Innovative Medicines | N/D | N/D | N/D |
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
L'ISS Governance QualityScore di Centessa Pharmaceuticals plc al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.